TY - JOUR T1 - Oncolytic Potential of a Novel KGFR Tyrosine Kinase Inhibitor Using a KGFR-selective Breast Cancer Xenograft Model JF - Anticancer Research JO - Anticancer Res SP - 47 LP - 52 VL - 35 IS - 1 AU - JASON W. KESINGER AU - MEGHNA MEHTA AU - MEGAN R. LERNER AU - DANIEL J. BRACKETT AU - ROBERT W. BRUEGGEMEIER AU - PUI-KUI LI AU - J. THOMAS PENTO Y1 - 2015/01/01 UR - http://ar.iiarjournals.org/content/35/1/47.abstract N2 - Background: Keratinocyte growth factor (KGF)/KGF receptor (KGFR) signaling produces a rapid increase in the progression of breast cancer. Molecular modeling was used to create a group of KGFR-selective kinase inhibitors (TKI). Compound L-27 is a potent and selective KGFR TKI. The present study examined the oncolytic potential of L-27 using a breast cancer xenograft model. Materials and Methods: An orthotopic xenograft model was developed with KGF-transfected MCF-7 cells to examine the influence of L-27 upon KGFR-mediated tumor progression. Results: L-27 was found to produce a dose-related reduction in the growth and metastasis of mouse xenograft tumors. Furthermore, L-27 treatment did not produce any signs of gross toxicity. Conclusion: L-27 was found to reduce the growth and metastasis of MCF-7 tumor xenografts with elevated expression of KGF. Thus, KGFR TKI may provide a new therapeutic approach for the treatment of breast and other types of cancer. ER -